{"schema_version":"secwatch.filing_event.v1","accession":"0001724521-24-000153","form_type":"8-K","ticker":"RCUS","cik":"0001724521","company_name":"Arcus Biosciences, Inc.","filed_at":"2024-10-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.369293+00:00","generated_at":"2026-05-30T10:34:08.716490+00:00","sec_items":["7.01","8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Arcus reports casdatifan interim data: 34% ORR in heavily pre-treated ccRCC patients","bullets":["ORR 34% (11/32) in efficacy-evaluable patients at 100 mg dose; confirmed ORR 25% (8/32).","Disease control rate 81%; median progression-free survival not reached (data cutoff Aug 30, 2024).","Patient population heavily pre-treated: 52% had ≥3 prior lines; 61% intermediate IMDC risk.","Grade 3 TEAEs related to casdatifan were 42% (anemia 36%, hypoxia 9%); no deaths or life-threatening events."],"urls":{"canonical":"https://secwatch.observer/filing/0001724521-24-000153","json":"https://secwatch.observer/filing/0001724521-24-000153.json","markdown":"https://secwatch.observer/filing/0001724521-24-000153.md","text":"https://secwatch.observer/filing/0001724521-24-000153.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1724521/000172452124000153/0001724521-24-000153-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1724521/000172452124000153/rcus-20241024.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T10:34:08.716490+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}